查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992138

核酸藥物市場：2026-2032年全球市場預測（依藥物類型、分子類型、給藥途徑、治療領域及最終用戶分類）

Nucleic Acid-Based Drugs Market by Drug Type, Molecule Type, Route of Administration, Therapeutic Area, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核酸藥物市值將達到 377.6 億美元，到 2026 年將成長至 427.7 億美元，到 2032 年將達到 934.6 億美元，複合年成長率為 13.82%。

主要市場統計數據
基準年 2025 377.6億美元
預計年份：2026年 427.7億美元
預測年份 2032 934.6億美元
複合年成長率 (%) 13.82%

對核酸療法的簡明策略展望，反映了科學突破、監管成熟度和產業擴充性的融合。

核酸療法已從一個小眾研究領域發展成為現代藥物研發的主流支柱，這得益於遞送系統、化學修飾和監管核准的突破性進展。近期臨床的成功和核准流程證明了曾經備受質疑的治療方法的合理性，科學界也正逐漸傾向於採用mRNA、 RNA干擾和反義技術等可擴展的方法。這些進展重塑了研發人員選擇標靶、進行患者分層和評估平台經濟性的方式，從而加快了從藥物發現到首次人體臨床試驗的週期。

技術平台化、監管澄清和供應鏈韌性如何重塑核酸療法領域的競爭格局？

核酸療法領域正經歷著一場變革性的轉變，這場轉變重新定義了競爭優勢和計畫可行性。技術的成熟——尤其是在遞送載體、脂質奈米顆粒化學和精確化學修飾方面的進步——已將許多先前難以攻克的標靶轉化為切實可行的治療機會。同時，平台思維也變得至關重要。各機構透過建構可重複使用的開發框架，縮短了研發週期，並降低了後續候選化合物的技術風險。這種平台化也正在改變投資模式，資本越來越傾向於那些擁有成熟轉換路徑的公司，而不是那些只有孤立治療概念的公司。

該評估旨在評估關稅趨勢如何推動核酸療法供應鏈的本地化、成本重新分配以及採購和製造方面的策略轉變。

貿易政策的變化以及關稅上調的前景可能會對核酸領域開發商和供應商的經濟狀況和產業計畫產生累積影響。進口關稅的提高將影響關鍵原料的成本基礎，例如修飾核苷酸、脂質組成、層析法樹脂和專用一次性耗材。隨著上游工程製程原料成本的上升，企業將面臨重新分配預算、優先考慮具有更清晰價值提案的專案或加快供應鏈本地化以維持獲利能力和進度確定性的壓力。

將藥物模式、分子類別、給藥途徑、治療領域和最終用戶行為與策略性研發和商業化選擇聯繫起來的詳細細分見解。

細分分析揭示了不同治療模式、分子類別、給藥途徑、治療領域和最終用戶群體的差異化趨勢，每種模式都需要不同的策略。根據藥物類型，研發人員必須權衡反義寡核苷酸、DNA/RNA適體、mRNA療法、核苷類似物和RNA干擾療法（RNA干擾療法又可細分為微型RNA、短髮夾RNA和短干擾RNA）的固有技術需求。投資於強調模組化化學和遞送方法的平台，可望涵蓋該頻譜內的多種亞型。根據分子類型，大分子和小分子需要不同的決策框架，這會影響生產複雜性、分析控制策略以及儲存和物流。

美洲、歐洲、中東、非洲和亞太地區的優勢和細微的監管差異如何決定創新、製造和商業化在哪些地區加速發展？

區域趨勢決定著創新、生產和商業化動力集中的地區，這需要在全部區域以地域為導向的策略。在美洲，生物技術產業叢集密集、資本獲取便利性以及監管柔軟性等因素共同推動了早期創新蓬勃發展，並促進了夥伴關係與衍生企業的積極交易。高效的臨床試驗基礎設施和病患招募機制支持快速概念驗證（PoC）試驗，同時，對國內生產的投資也日益受到重視，以應對供應鏈和關稅風險。

決定哪些參與者能夠加速發展、實現規模化並獲得商業性價值的策略性企業原型和必要的夥伴關係要求。

競爭格局由垂直整合的研發公司、專業平台供應商、合約研發生產機構 (CDMO) 以及試劑和設備供應商共同構成，它們緊密結合，形成一個完整的生態系統。領先的研發公司憑藉平台可重複性、成熟的臨床應用以及建立策略夥伴關係關係的能力脫穎而出，從而降低後期研發風險。提供遞送系統、新型化學技術或先進分析技術的專業平台供應商，透過支援多個治療項目並降低合作夥伴的技術不確定性，正獲得顯著的影響力。

為領導者提供極具影響力的建議，將技術進步轉化為業務韌性、監管應對力和商業性可行性。

行業領導者應採取重點策略，將科學洞見與業務韌性和商業性清晰度相結合。首先，優先投資於能夠實現適應症和治療方法以外的重複利用的平台。此類平台可降低額外的研發風險，並加速下一代專案的推進。其次，提高供應鏈透明度，實現關鍵原料供應商多元化，並探索區域製造夥伴關係，以降低關稅和物流風險。第三，從專案設計的早期階段就整合監管和品質方面的專業知識，以簡化對比測試、交付前測試和CMC（化學、生產和品管）流程安排。

採用透明且多方面的調查方法，結合專家訪談、技術文獻、監管審查和情境分析，以檢驗關鍵發現。

本摘要的研究採用多方面方法，結合第一手資料和二手資料，以確保其可靠性和相關性。第一手資料包括對開發人員、生產專家和監管專家的結構化訪談，以及對近期同行評審文獻和臨床試驗註冊資訊的整合，重點關注核酸療法。二手資料涵蓋技術評論、專利趨勢和已發布的監管指導文件，以反映品質、安全性和分析要求方面不斷變化的預期。

結論強調，整合平台能力、監管前瞻性和供應鏈韌性是核酸療法長期成功的關鍵。

核酸療法是現代醫學中一個強大且快速發展的支柱，其特點是技術創新、監管知識的累積和營運重點的不斷變化。該領域獨特地融合了科學機會和物流複雜性。成功不僅取決於生物學創新，還取決於生產品質、供應鏈韌性以及與監管機構和支付方流程的策略協調。整合平台能力、儘早與監管機構溝通並採用地理均衡的供應策略的相關人員，最有能力將科學潛力轉化為商業性和臨床成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：核酸類藥物市場（依藥物類型分類）

  • 反義寡核苷酸
  • DNA/RNA適體
  • 基於mRNA的療法
  • 核苷類似物
  • RNA干擾（RNAi）治療藥物
    • 微型RNA（miRNA）
    • 短髮夾RNA（shRNA）
    • 短干擾RNA（SiORNA）

第9章：依分子類型分類的核酸藥物市場

  • 聚合物
  • 低分子

第10章：核酸藥物市場：依給藥途徑分類

  • 吸入
  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下

第11章：核酸藥物市場：依治療領域分類

  • 心血管疾病
  • 感染疾病
    • 細菌感染疾病
    • 黴菌感染疾病
    • 病毒感染疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌
  • 罕見疾病

第12章：核酸藥物市場：依最終用戶分類

  • 學術和研究機構
  • 合約研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第13章 核酸藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：核酸藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 核酸藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國核酸藥物市場

第17章：中國核酸藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Beam Therapeutics Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • Generation Bio Co.
  • Gilead Sciences, Inc.
  • GSK PLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics NV
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics PLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.
Product Code: MRR-CA7E340319CE

The Nucleic Acid-Based Drugs Market was valued at USD 37.76 billion in 2025 and is projected to grow to USD 42.77 billion in 2026, with a CAGR of 13.82%, reaching USD 93.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 37.76 billion
Estimated Year [2026] USD 42.77 billion
Forecast Year [2032] USD 93.46 billion
CAGR (%) 13.82%

A concise strategic orientation to nucleic acid therapeutics reflecting the convergence of scientific breakthroughs, regulatory maturation, and industrial scalability

Nucleic acid-based therapeutics have transitioned from niche research curiosities to a mainstream pillar of modern drug development, driven by breakthroughs in delivery systems, chemical modification, and regulatory acceptance. Recent clinical successes and authorization pathways have validated modalities that once faced skepticism, and the scientific community has coalesced around scalable approaches for mRNA, RNA interference, and antisense technologies. These advances have reshaped how developers approach target selection, patient stratification, and platform economics, enabling more agile cycles from discovery to first-in-human trials.

The industry now operates at the intersection of precision biology and industrial biotechnology. Improvements in synthesis, purification, and analytics have reduced historical barriers, while modular platform design has accelerated translational timelines. At the same time, regulatory authorities have matured their frameworks to address modality-specific safety and quality concerns, increasing predictability for developers. As a result, decision-makers must balance scientific opportunity with practical considerations such as manufacturing scalability, supply chain robustness, and global regulatory alignment.

This executive summary synthesizes core trends shaping the field and delivers insights that leaders can apply to R&D prioritization, partnership selection, and operational planning. The aim is to present a concise, evidence-based perspective that supports strategic choices across discovery, clinical development, and commercialization.

How technological platformization, regulatory clarity, and supply chain resilience are reshaping competitive dynamics across the nucleic acid therapeutics landscape

The landscape for nucleic acid therapies has undergone transformative shifts that redefine competitive advantage and program viability. Technological maturation-particularly in delivery vectors, lipid nanoparticle chemistries, and precise chemical modifications-has converted many previously intractable targets into realistic therapeutic opportunities. Concurrently, platform thinking has become central: organizations build reusable development frameworks that shorten timelines and reduce technical risk for subsequent candidates. This platformization has changed investment patterns, as capital increasingly favors entities with demonstrated translational pathways rather than one-off therapeutic concepts.

Regulatory evolution has been equally consequential. Agencies have issued clearer guidances on quality attributes, control strategies, and clinical endpoints specific to nucleic acid modalities. This greater clarity reduces regulatory uncertainty and supports parallel investments in manufacturing and analytic capabilities. At the same time, the ecosystem of contract development and manufacturing organizations has expanded and specialized, enabling smaller developers to access GMP production and advanced analytics without owning large capital footprints.

Geopolitical influences and supply chain considerations now play a larger role in project planning. Sourcing of raw materials, specialized reagents, and instrumentation is more strategic, and companies actively diversify suppliers and regionalize certain production steps to mitigate disruption risk. Together, these shifts emphasize adaptability, resilience, and the importance of integrating scientific, regulatory, and operational strategies early in program planning.

Assessing how tariff dynamics are driving supply chain regionalization, cost reallocation, and strategic shifts in sourcing and manufacturing for nucleic acid therapies

Trade policy changes and the prospect of elevated tariffs can have a cumulative impact on the economics and operational planning of developers and suppliers in the nucleic acid sector. Increased import duties affect the cost base for critical inputs such as modified nucleotides, lipid components, chromatography resins, and specialized single-use consumables. When upstream input costs rise, organizations face pressure to reallocate budgets, prioritize programs with clearer value propositions, or accelerate localization of supply chains to preserve margin and timeline certainty.

Beyond direct cost implications, tariffs can influence strategic behavior. Companies may respond by reconfiguring supply chains to reduce cross-border movements of high-value components, investing in domestic manufacturing capacity to avoid tariff exposure, or renegotiating supplier contracts to shift risk. These adjustments carry operational lead times and capital implications; decisions to insource or regionalize production require rigorous assessment of technical feasibility, regulatory implications, and long-term demand stability.

Tariff pressure also affects collaboration models and licensing negotiations. When manufacturing costs and timelines become less predictable, counterparties increasingly structure agreements with contingency clauses and staged milestones tied to supply stability. For organizations that depend on global networks for materials and services, proactive scenario planning is essential to maintain development momentum. Ultimately, the cumulative impact of tariffs is not solely economic; it reshapes strategic priorities, accelerates regional manufacturing initiatives, and heightens the value of supply chain visibility and contractual flexibility.

Deep segmentation insights connecting drug modality, molecule class, administration route, therapeutic focus, and end-user behaviors to strategic R&D and commercialization choices

Segmentation analysis reveals divergent dynamics across modalities, molecular classes, administration routes, therapeutic areas, and end users that require differentiated strategies. Based on drug type, developers must balance the unique technical demands of antisense oligonucleotides, DNA/RNA aptamers, mRNA-based therapeutics, nucleoside analogs, and RNA interference therapeutics, with RNA interference further subdivided into microRNA, short hairpin RNA, and short interfering RNA; platform investments that favor modular chemistry and delivery approaches can unlock multiple subtypes within this spectrum. Based on molecule type, decision frameworks differ for large molecules compared to small molecules, influencing manufacturing complexity, analytical control strategies, and storage logistics.

Route of administration is a critical determinant of formulation strategy and commercial positioning; inhalation, intramuscular, intravenous, oral, and subcutaneous routes each impose distinct delivery, stability, and patient adherence considerations that influence clinical design and manufacturing specifications. Therapeutic area segmentation highlights how scientific and commercial risk profiles vary: cardiovascular, infectious, metabolic, neurological, oncology, and rare diseases each present different biomarker needs, regulatory pathways, and patient populations, with infectious disease indication suites spanning bacterial, fungal, and viral infections and oncology distinguished by hematologic malignancies versus solid tumors. Based on end-user, utilization patterns and procurement models diverge between academic and research institutes, contract research organizations, hospitals and clinics, and pharmaceutical and biotechnology companies, shaping demand for specialized services, analytic packages, and partnership models.

Collectively, these segmentation lenses enable tailored go-to-market and R&D strategies. Portfolio prioritization should align modality strengths with unmet clinical needs and operational readiness, while manufacturing and quality investments must be matched to anticipated administration routes and end-user requirements to minimize translational friction.

How regional strengths and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific determine where innovation, manufacturing, and commercialization accelerate

Regional dynamics are defining where innovation, production, and commercialization momentum concentrate, requiring geographically informed strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, a combination of dense biotech clusters, capital availability, and regulatory agility drives robust early-stage innovation and high transaction activity for partnerships and spinouts. Clinical trial infrastructures and patient recruitment efficiencies support rapid proof-of-concept studies, while domestic manufacturing investments are increasingly prioritized to manage supply chain exposure and tariff risk.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and specialized public-private initiatives support translational pipelines, yet developers must navigate heterogeneous national reimbursement frameworks and varied clinical trial ecosystems. European manufacturing capacity emphasizes quality and technical specialization, often in close collaboration with academic centers to translate platform science. In the Asia-Pacific region, rapid expansion of technical capabilities, competitive manufacturing costs, and growing clinical capacities create attractive conditions for scale-up and late-phase development. Regional regulatory agencies are progressively modernizing frameworks and expanding expedited pathways, and local demand for innovative therapies is rising alongside government investments in biotech infrastructure.

Successful players tailor engagement models by region, aligning partnerships, manufacturing footprints, and regulatory strategies with local strengths. Executing regional playbooks that account for clinical operations, supply chain logistics, and market access nuances will determine the speed and sustainability of commercial rollouts.

Strategic company archetypes and partnership imperatives that dictate which players will accelerate development, enable scalability, and capture commercial value

Competitive landscapes are shaped by a mix of vertically integrated developers, specialist platform providers, contract development and manufacturing organizations, and reagent and instrument suppliers that together form a dense ecosystem. Leading developers differentiate through platform repeatability, demonstrated clinical translation, and the ability to secure strategic partnerships that de-risk late-stage development. Specialist platform providers that offer delivery systems, novel chemistries, or advanced analytics gain outsized influence because they enable multiple therapeutic programs and reduce technical uncertainty for partners.

Contract development and manufacturing organizations remain pivotal, providing access to GMP production, scale-up expertise, and regulatory support-particularly for organizations that prefer asset-light models. Suppliers of critical raw materials and analytical instruments hold strategic importance; their quality, lead times, and geographic footprint directly influence program timelines. Additionally, service providers offering regulatory intelligence, clinical operations tailored to nucleic acid modalities, and market access consulting play an increasingly central role in shaping successful launch strategies.

For decision-makers evaluating partnerships or M&A, the most attractive targets combine strong technical differentiation, reproducible manufacturing processes, and embedded regulatory experience. Assessments should prioritize proven scalability, IP robustness, and the flexibility to support multiple modalities across therapeutic areas.

High-impact recommendations for leaders to convert technological advances into operational resilience, regulatory readiness, and commercial execution

Industry leaders should adopt targeted strategies that align scientific capability with operational resilience and commercial clarity. First, prioritize platform investments that enable reuse across indications and modalities; such platforms reduce marginal development risk and accelerate next-generation programs. Second, build supply chain visibility and diversify suppliers for critical inputs, while exploring regional manufacturing partnerships to mitigate tariff and logistic exposure. Third, integrate regulatory and quality expertise early in program design to streamline comparability, release testing, and CMC timelines.

In parallel, structure partnerships and commercial agreements to reflect supply and regulatory uncertainties, using milestone-based frameworks, shared-risk manufacturing arrangements, and flexible licensing terms. Invest in translational analytics and biomarker strategies to sharpen patient selection and strengthen value dossiers for payers. Operationally, expand capabilities in advanced analytics, process characterization, and digital quality systems to improve batch consistency and support regulatory confidence. Finally, cultivate a talent pipeline that blends molecular biology, process engineering, and regulatory science, ensuring that cross-functional teams can translate platform innovations into reliable clinical and commercial outputs.

Adopting these actions will help organizations convert scientific advances into durable, scalable programs while preserving optionality amid shifting policy and market conditions.

A transparent multi-method research methodology combining expert interviews, technical literature, regulatory reviews, and scenario analysis to validate key insights

The research underpinning this summary draws on a multi-method approach combining primary and secondary evidence to ensure robustness and relevance. Primary inputs included structured interviews with developers, manufacturing specialists, and regulatory experts, as well as synthesis of recent peer-reviewed literature and clinical trial registries focused on nucleic acid modalities. Secondary sources encompassed technological reviews, patent landscapes, and public regulatory guidance documents to map evolving expectations around quality, safety, and analytical requirements.

Analytic methods integrated thematic synthesis of expert interviews with comparative assessments of manufacturing pathways, supply chain configurations, and route-of-administration considerations. Scenario analysis was employed to evaluate the operational implications of trade policy shifts and supply disruptions, while cross-regional comparisons identified regulatory and infrastructure differentials that influence program timelines. Quality control procedures included source triangulation, expert validation of key inferences, and a transparency log documenting data provenance and methodological choices.

This mixed-methods approach balances depth and breadth, providing a defensible foundation for strategic recommendations and enabling targeted follow-up analyses tailored to specific programs or operational questions.

Concluding synthesis emphasizing that integrated platform capabilities, regulatory foresight, and supply chain resilience determine long-term success in nucleic acid therapeutics

Nucleic acid therapeutics represent a durable and rapidly evolving pillar of modern medicine, characterized by technological innovation, regulatory learning, and shifting operational priorities. The field presents a unique combination of scientific opportunity and logistical complexity: success depends not only on biological innovation but also on manufacturing quality, supply chain resilience, and strategic alignment with regulatory and payer pathways. Stakeholders that integrate platform capabilities, early regulatory engagement, and geographically aware supply strategies are best positioned to convert scientific promise into commercial and clinical impact.

Moving forward, organizations should treat platform development and operational readiness as co-equal strategic objectives. By doing so, they can retain the agility to pursue diverse indications while ensuring that late-stage requirements do not create bottlenecks. The ability to anticipate policy shifts, diversify supply channels, and craft flexible partnerships will determine which programs progress efficiently and which face avoidable delays. Ultimately, the most successful actors will be those that combine deep scientific expertise with disciplined execution across manufacturing, regulatory, and commercial domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid-Based Drugs Market, by Drug Type

  • 8.1. Antisense Oligonucleotides
  • 8.2. DNA/RNA Aptamers
  • 8.3. mRNA-Based Therapeutics
  • 8.4. Nucleoside Analogs
  • 8.5. RNA Interference (RNAi) Therapeutics
    • 8.5.1. MicroRNA (MiRNA)
    • 8.5.2. Short Hairpin RNA (ShRNA)
    • 8.5.3. Short Interfering RNA (SiRNA)

9. Nucleic Acid-Based Drugs Market, by Molecule Type

  • 9.1. Large Molecule
  • 9.2. Small Molecule

10. Nucleic Acid-Based Drugs Market, by Route of Administration

  • 10.1. Inhalation
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Nucleic Acid-Based Drugs Market, by Therapeutic Area

  • 11.1. Cardiovascular Diseases
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Fungal Infections
    • 11.2.3. Viral Infections
  • 11.3. Metabolic Disorders
  • 11.4. Neurological Disorders
  • 11.5. Oncology
    • 11.5.1. Hematologic Malignancies
    • 11.5.2. Solid Tumors
  • 11.6. Rare Diseases

12. Nucleic Acid-Based Drugs Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Nucleic Acid-Based Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nucleic Acid-Based Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nucleic Acid-Based Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nucleic Acid-Based Drugs Market

17. China Nucleic Acid-Based Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alnylam Pharmaceuticals, Inc.
  • 18.6. Amgen Inc.
  • 18.7. Arcturus Therapeutics Holdings Inc.
  • 18.8. Arrowhead Pharmaceuticals, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Beam Therapeutics Inc.
  • 18.11. Biogen, Inc.
  • 18.12. BioMarin Pharmaceutical Inc.
  • 18.13. BioNTech SE
  • 18.14. Bluebird Bio, Inc.
  • 18.15. CRISPR Therapeutics AG
  • 18.16. CureVac N.V.
  • 18.17. Dynavax Technologies Corporation
  • 18.18. Editas Medicine, Inc.
  • 18.19. Eli Lilly and Company
  • 18.20. Evotec SE
  • 18.21. F. Hoffmann-La Roche Ltd.
  • 18.22. Generation Bio Co.
  • 18.23. Gilead Sciences, Inc.
  • 18.24. GSK PLC
  • 18.25. Intellia Therapeutics, Inc.
  • 18.26. Ionis Pharmaceuticals, Inc.
  • 18.27. Merck & Co., Inc.
  • 18.28. Moderna, Inc.
  • 18.29. Novartis AG
  • 18.30. Novo Nordisk A/S
  • 18.31. Orna Therapeutics, Inc.
  • 18.32. Pfizer Inc.
  • 18.33. ProQR Therapeutics N.V.
  • 18.34. Sangamo Therapeutics, Inc.
  • 18.35. Sanofi SA
  • 18.36. Sarepta Therapeutics, Inc.
  • 18.37. Silence Therapeutics PLC
  • 18.38. Stoke Therapeutics, Inc.
  • 18.39. Takeda Pharmaceutical Company Limited
  • 18.40. Vertex Pharmaceuticals Incorporated
  • 18.41. Voyager Therapeutics, Inc.
  • 18.42. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 190. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)